couter

SIGASIGA Technologies, Inc.

Health CarePharmaceuticals
Oct 15, 2026 — BARDA Pipeline & International TPOXX Procurement Update
Chart by TradingView

The schedule

  • Thu15Oct

    Expected mid-Q4 update regarding biosecurity stockpiling demand and the Trump administration's defense and health security allocations.

  • Wed20Jan

    Draft formulations for the FY2027 defense and health security budgets under the Trump administration will clarify forward funding for biodefense.

  • Tue2Feb

    Q3 print focusing on revenue lumpiness and whether international orders have successfully transitioned into recognized operating cash flow.

  • Tue4May

    Full-year results and initial FY2027 revenue guidance, crucial for modeling the lumpiness of domestic government and international deliveries.

  • Tue3Aug

    Q1 earnings release evaluating margin stabilization and early-year progress on international TPOXX commercialization.

Past

  • Tue4Aug

    Actual outcome: Bear

    SIGA reported Q2 product-related revenue of $38 million and met EPS estimates of -$0.0482. However, the stock declined as results highlighted the variable timing of its government-focused procurement business, failing to alleviate investor concerns over revenue visibility and BARDA contract renewals.

    SIGA reports Q2 results with the market heavily focused on international TPOXX procurement and domestic delivery schedules.

  • Tue10Mar

    Actual outcome: Bear · $5.02 at outcome

    SIGA reported Q4 EPS of -$0.09, matching analyst estimates exactly, while management provided conservative FY2026 guidance regarding the timing of international and domestic delivery schedules. The stock remained flat as the lack of an earnings surprise was offset by cautious forward-looking commentary, leaving the price trading in the middle of the bull and bear range as of the run date.

    SIGA reported Q4 EPS of -$0.09, matching analyst estimates exactly, while management provided conservative FY2026 guidance regarding the timing of international and domestic delivery schedules. The stock remained flat as the lack of an earnings surprise was offset by cautious forward-looking commentary, leaving the price trading in the middle of the bull and bear range as of the run date.